VANCOUVER, British Columbia, June 7, 2011 /CNW/ -- Abattis Biologix Corporation (CNSX: FLU) announced today they have learned that the U.S. Government has charged Dr. Charles Hensley with unlawfully importing and distributing an unapproved herbal product named, "Vira 38," in 2005. The federal indictment further charges that Dr. Hensley unlawfully credited Vira 38 with treating bird flu without FDA approval.
Recently, Abattis obtained all rights, title and interest to Dr. Hensley's patent portfolio on the use of an antiviral technology in humans and poultry. "The efficacy data is compelling and supports the patent claims made by Dr. Hensley when originally filed, particularly when the product was compared to the popular influenza drug Oseltamivir. For example, Dr. Hensley's research indicated that the compound in Vira 38 outperformed Oseltamivir and significantly shortened the duration of flu symptoms. Individuals taking the compounds in the Vira 38 product saw significant decreases in symptoms within an average of 2.1 days," commented Mike Withrow, CEO of Abattis.
"Abattis' decision to acquire the intellectual property assets of Hensley and his partners were based on this efficacy data, which we believe is sound," said Withrow. "The charges against Dr. Hensley are based on how he labeled, marketed and imported the product, and have no bearing on the efficacy or usefulness of the formulas we acquired if they are properly marketed in the United States," noted Withrow. In addition, Abbatis is planning to conduct further research to support the existing efficacy data.
"We firmly believe that our approach of using botanical extracts with demonstrated anti-bacterial and anti-viral action is an important effort to bring consumers safe, effective natural alternatives with meaningful benefits for both human and animal use," Withrow said.
About Abattis Biologix
Abattis Biologix Corporation is committed to the research, development and marketing of proprietary, natural health and wellness solutions that address chronic illnesses through targeted nutritional support. We manufacture and market the most scientifically advanced natural therapeutic formulas based on proprietary technologies through multiple distribution channels, while providing the highest level of customer service.
Media Contact: Margie Adelmanmadelman@adelmanpr.com 916 220 3500
SOURCE Abattis Biologix Corporation